The use of vaccines in the prevention and treatment of cervical cancer

Clinical Oncology

Volumn 14, Issue 3, 2002, Pages 193-200

  Davidson, Emma J ^a,b   Kitchener, Henry C ^b   Stern, Peter L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; PEPTIDE; PROTEIN; TUMOR ANTIGEN; VIRUS VACCINE; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; CANCER SCREENING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; PRECANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DISEASE; VACCINATION; VIRUS INFECTION; WART VIRUS; ANIMAL; IMMUNOLOGY; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY;

ANIMALS; CANCER VACCINES; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0036593909     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2002.0056     Document Type: Review

References (85)

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
2. Third report of the International Committee on Taxonomy of Viruses. Classification and nomenclature of viruses
3. Papillomavirus, p53 alteration and primary carcinoma of the vulva
4. Molecular genetics of human papillomaviruses
5. Papillomaviruses: Particles, genome organization and proteins
6. Virus-keratinocyte interactions in the infectious cycle
7. Interaction of papillomaviruses with the cell surface
8. Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein
9. Identification of the alpha(6) integrin as a candidate receptor for papillomaviruses
10. The functions of human papillomavirus type 11 E1, E2 and E2c proteins in cell-free DNA replication
11. Co-operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro
12. Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus
13. The papillomavirus E2 regulatory proteins
14. HPV oncoprotein function
15. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias
16. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization
17. The E4 proteins and their role in the viral life cycle
18. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
19. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage
20. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product
21. Structure and transcription of HPV sequences in cervical carcinoma cells
22. Molecular analysis of integrated human papillomavirus 16 sequences in the cervical cancer cell line SiHa
23. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: Preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames
24. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity
25. HPV immortalisation and transformation
26. High risk human papillomavirus in cytomorphological normal smears has a high predictive value for development of severe dysplasia
27. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins
28. Epidemiology of cervical human papillomavirus infections
29. Natural history of genital human papillomavirus infections
30. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
31. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
32. Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens
33. Decreased T cell levels in patients with warts
34. Immunosuppression as a high-risk factor in the development of condyloma accuminata and squamous neoplasia of the cervix
35. HPV and lower genital tract neoplasia in renal transplant patients
36. Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection
37. Morphometric analysis and identification of infiltrating leucocytes in regressing and progressing Shope rabbit papillomas
38. Immunological events in regressing genital warts
39. The cellular immune response to human papillomavirus infection
40. A virus-like particle enzyme-linked-immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type-16
41. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain
42. Papillomavirus lesions in immunodepression and immunosuppression
43. Human cellular immune responses against human papillomaviruses in cervical neoplasia
44. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T lymphocytes
45. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia
46. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
47. Papillomavirus-like particles and HPV vaccine development
48. Prospects for human papillomavirus vaccine development: Emerging HPV vaccines
49. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
50. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
51. Immunisation with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
52. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunisation
53. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
54. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: A canine model
55. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
56. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
57. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies
58. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
59. Public Health Paradoxes and the epidemiological impact of an HPV Vaccine
60. Estimates of the worldwide incidence of 25 major cancers in 1990
61. Chimeric papillomavirus virus-like particles elicit anti-tumour immunity against the E7 oncoprotein in an HPV16 tumour model
62. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination
63. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials
64. Papillomavirus Vaccines
65. Cell mediated immunity to papillomaviruses
66. Constimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin production and immunotherapy
67. Tumour antigens recognised by T cells
68. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: Protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection
69. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells
70. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18
71. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA
72. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
73. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
74. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design
75. Safety and immunogenicity of HPV 16 E7/algammulin
76. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
77. Protection against papillomavirus with a polynucleotide vaccine
78. Immunisation with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumour cells
79. Reconstitution of viral immunity in immunocompromised humans by adoptive transfer of T-cell clones
80. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
81. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity
82. The prime-boost strategy: Exciting prospects for improved vaccination
83. Multifocal vulva: Intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus
84. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression
85. Human papillomavirus vaccines for cervical cancer